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Abstract
Corneal collagen cross-linking (CXL) has been described as a promising therapy for keratoconus. According to standard CXL
protocol, epithelium should be debrided before treatment to allow penetration of riboflavin into the corneal stroma.
However, removal of the epithelium can increase procedure risks. In this study we aim to evaluate stromal penetration of a
biocompatible riboflavin-based nanoemulsion system (riboflavin-5-phosphate and riboflavin-base) in rabbit corneas with
intact epithelium. Two riboflavin nanoemulsions were developed. Transmittance and absorption coefficient were measured
on corneas with intact epithelia after 30, 60, 120, 180, and 240 minutes following exposure to either the nanoemulsions or
standard 0.1% or 1% riboflavin-dextran solutions. For the nanoemulsions, the epithelium was removed after measurements
to assure that the riboflavin had passed through the hydrophobic epithelium and retained within the stroma. Results were
compared to de-epithelialized corneas exposed to 0.1% riboflavin solution and to the same riboflavin nanoemulsions for
30 minutes (standard protocol). Mean transmittance and absorption measured in epithelialized corneas receiving the
standard 0.1% riboflavin solution did not reach the levels found on the debrided corneas using the standard technique.
Neither increasing the time of exposure nor the concentration of the riboflavin solution from 0.1% to 1% improved
riboflavin penetration through the epithelium. When using riboflavin-5-phosphate nanoemulsion for 240 minutes, we
found no difference between the mean absorption coefficients to the standard cross-linking protocol (p= 0.54). Riboflavin
nanoemulsion was able to penetrate the corneal epithelium, achieving, after 240 minutes, greater stromal concentration
when compared to debrided corneas with the standard protocol (p= 0.002). The riboflavin-5-phosphate nanoemulsion
diffused better into the stroma than the riboflavin-base nanoemulsion.
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Introduction
Corneal collagen cross-linking (CXL) has emerged as a
promising and innovative treatment for progressive keratoconus
and surgically-related ectasia [1]. Recently, a significant number of
studies have used this treatment for a wider range of applications,
including microbial keratitis [2] and prevention of keratectasia
prior to refractive surgery [3]. The standard CXL protocol
proposed by Wollensak et al. recommended removal of the
epithelium before treatment to allow penetration of riboflavin into
the stroma [1]. Experimental and clinical investigations have
shown that the intact epithelium does not block the effect of
ultraviolet A (UVA) light [4], but decreases the effectiveness of the
treatment by impairing the adequate stromal diffusion of riboflavin
[5–11]. However, de-epithelialization is not risk-free and can
increase the rate of corneal infections, haze, scarring, and
infiltrates [12–16]. Moreover, it can cause postoperative pain,
photophobia, and delayed visual rehabilitation [1]. Some modi-
fications of the initial treatment have been suggested to overcome
these disadvantages. Studies reported the use of benzalkonium
chloride (BAK) to loosen tight junctions of corneal epithelial cells
and facilitate riboflavin stromal diffusion [9,17]. However, both in
vitro and in vivo studies have demonstrated adverse effects of BAK
on epithelial cell populations [18–21]. Recently, BAK-induced
corneal neurotoxicity has been demonstrated [21]. Riboflavin in
association with anesthetic drops poorly penetrated the cornea [7],
and even superficial epithelial trauma was not sufficient to permit
the adequate penetration of riboflavin into the stroma. Samaras et
al. confirmed these findings not being able to increase penetration
of riboflavin by using 20% alcohol in one group, and a grid pattern
epithelial debridement in another group [6]. Neither groups had
an acceptable and homogeneous riboflavin penetration. Further-
more, prolonging the exposure time to standard hydrophilic
riboflavin did not lead to increased stromal saturation in corneas
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with intact epithelium [22]. Other alternatives to avoid complete
epithelial debridement include a central corneal pocket created by
a femtosecond laser that allows for direct intrastromal drug
administration [23,24]. However, one should be concerned
regarding biomechanical stability after stromal dissection by the
femtosecond laser. A riboflavin complex, with edetate disodium
(EDTA) and tromethamine, has been tested for transepithelial
CXL. However, due to its limited permeation through the
epithelium, the CXL effect was reduced [25]. Recently, cyclodex-
trins were successfully used to enhance riboflavin solubility in
water and to improve its permeability through fresh and
cryopreserved bovine corneas [26]. In summary, none of the
present modalities has proven to be clinically effective in delivering
an adequate intrastromal concentration of riboflavin, hence a
better method still needs to be developed.
Formulation is the most important factor in facilitating
penetration of riboflavin through the epithelium. The standard
riboflavin solution (10 mg riboflavin-5-phosphate in 10 mL 20%
dextran T-500) has hydrophilic characteristics that prevent full
diffusion of this drug through the lipophilic epithelium. Moreover,
the electrostatic repulsion between the anionic riboflavin-5-
phosphate and the negatively charged surface of the cornea
further reduces its epithelial penetration.
Considering physicochemical properties, both, riboflavin-base
and riboflavin-5-phosphate have no ability to permeate the cornea
epithelium and achieve access to the stroma. Due to its lipophilic
characteristic, riboflavin-base interacts with the epithelium and do
not achieve adequate concentration into stroma. On the other
hand, due to both hydrophilic property and the anionic character
that is strongly repelled by the cornea epithelium, the hydrophilic
riboflavin-5-phosphate does not sufficiently permeate to the
stroma [27]. Thus, an appropriated vehicle should associate both
bioadhesive and amphiphilic properties to allow the riboflavin to
penetrate the epithelium and diffuse into the corneal hydrophilic
stroma. In the present study we evaluated stromal absorption of
two different BAK-free, amphiphilic riboflavin-based nanoemul-
sions (riboflavin-5-phosphate and riboflavin-base) in rabbit corneas
with intact epithelium.
Materials and Methods
Ethics Statement
All procedures were carried out in accordance with the
institutional guideline for the care and use of laboratory animals
at the Federal University of Sa˜o Paulo. The experimental protocol
was approved by the Ethics in Research Committee of the Federal
University of Sa˜o Paulo, under the number 1565/07.
Riboflavin Ocular Formulations
Four riboflavin formulations were tested in this study:
A. 0.1% riboflavin-5-phosphate solution: A standard hydrophilic
riboflavin in dextran was prepared. This is the same
formulation used routinely in the standard CXL procedure.
The solution is comprised of 10 mg riboflavin-5-phosphate
dissolved in 10 mL 20% dextran T-500 (400 mOsm/mL).
B. 1% riboflavin-5-phosphate solution: A concentrated hydro-
philic riboflavin in dextran was prepared. This solution is
comprised of an increased concentration of riboflavin-5-
phosphate (in 20% dextran T-500) to study the effect of
riboflavin concentration on the absorbance of epithelialized
corneas.
C. 0.5% riboflavin-5-phosphate nanoemulsion: Nanoemulsions
containing soy phosphatidylcholine (SPC) (12% w/w),
polyoxyethylene sorbitan monolaurate (Tween) (12% w/w)
and ethylene oxide/propylene oxide block copolymer
(Pluronic) (2% w/w) as surfactant; propylene glycol dicapry-
late/dicaprate (5% w/w) (Captex) as oil phase; stearylamine
(0.3% w/w) as cationic agent; saline as aqueous phase (68,2%
w/w) and riboflavin-5-phosphate (0.5% w/w) were obtained
by sonication. For preparation SPC, Tween, Pluronic and
stearylamine were completely homogenized with the oil
phase Captex. Riboflavin-5-phosphate was dissolved in the
aqueous phase. The aqueous phase containing riboflavin-5-
phosphate was added to the lipid phase by vortexing the
mixture, and treated with ultrasound irradiation for up to
15 minutes using a probe-tip sonicator (600 watts of nominal
power) using 1 minute pulses and 1 minute intervals.
D. 0.5% riboflavin-base nanoemulsion: Nanoemulsions were
prepared in a similar manner by sonication using riboflavin-
base. SPC, Tween, Pluronic, stearylamine and riboflavin-
base were completely homogenized with the oil phase
Captex. The aqueous phase was added to the lipid phase
by vortexing the mixture, and treated with ultrasound
irradiation for up to 15 minutes using a probe-tip sonicator
(600 watts of nominal power) using 1-minute pulses and 1-
minute intervals.
Nanoemulsions can be defined as submicron sized oil-in-water
(o/w) emulsions with mean droplet diameters usually ranging from
10 to 100 nm [28]. These colloidal systems show a translucent
appearance and have been used for different applications in the
pharmaceutical fields [29,30]. They are prepared by high-energy
transfer processes, such as ultrasound irradiation and high-
pressure homogenization and do not show a separation phase
during storage [31].
Different interactions can occur with cationic nanodroplets
depending on the ionic specie of riboflavin tested. Neutral
riboflavin-base predominantly interacts by hydrophobic effect
with the nanoemulsion oil core [32]. On the other hand, the
anionic riboflavin-5-phosphate primarily interacts by electrostatic
effect with the positively charged droplets of nanoemulsions, and
also by the hydrophobic contribution of the non-ionic region of the
molecule [33].
For drug-unloaded nanoemulsions used in this study, the light
scattering measurements of the diameters, polydispersity index and
zeta potential are shown in Table 1. Regardless the presence of the
riboflavin, the obtained diameters values demonstrate that the
nanodroplets were efficiently formed with the stabilizing agents
used in the formulations. The polydispersity index less than 0.3
indicates excellent homogeneity in the droplets diameters distri-
bution. Furthermore, the values obtained for the zeta potential in
the range of 30–40 mV are indicative of excellent dispersion of the
nanodroplets in the bulk vehicle. However, when riboflavin was
incorporated into nanoemulsions the mean diameter increased to
about 78 nm for the riboflavin-5-phosphate and 82 nm for
riboflavin-base, both with polydispersity index less than 0.3
(Table 1). This increase in diameter of the nanodroplets shows a
swelling of the local volume of the dispersed oil phase demon-
strating that riboflavin was incorporated into nanoemulsions.
Increases of the local volume of oil droplet are a common feature
in drug delivery from colloidal systems such as micro- and
nanoemulsions [34,35].
The systems remained stable, optically semi-transparent and no
phase separation or solid sediment was observed after centrifuga-
tion 8,500 (6 g) for 15 min.
For both, empty and riboflavin-loaded nanoemulsions, the
droplet size control up to 180 days showed that there was an
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increase in the diameter of 7.5%. The increased diameter followed
zero-order kinetics, as described by straight-line equations. The
data of Figure 1 show that, although the incorporation of the
riboflavin into nanoemulsion resulted in an increase in the
diameter of the droplets throughout the length of the curve, the
lines describing the increase in size during the control of stability
have similar slope coefficients.
Equations 1 and 2 describe the increased diameter versus time
in unloaded and loaded nanoemulsions, respectively.
f (y)~68:612z0:030|time ð1Þ
f (y)~78:312z0:033|time ð2Þ
These results demonstrate that the incorporation of the
riboflavin into nanoemulsion did not affect the stability of the
system.
Evaluating equations 1 and 2, as well as the data shown in
Figure 1, it is possible to estimate that within two years of storage
the average diameters of nanodroplets will increase to 89.7 nm for
unloaded nanoemulsions and to 102.1 nm for riboflavin-5-loaded
nanoemulsion. The concentration of riboflavin in the nanoemul-
sion protected from light, measured up to 180 days, in the stability
test, was not less than 97%. Under these conditions the system
remains stable in its colloidal dispersion and the riboflavin content
suitable for obtaining the desired effect.
Furthermore, we have found that the drug recovery after
filtration through 0.22 mm membrane filter was always greater
than 95% of the added drug, regardless the ionic specie of the
incorporated riboflavin. The nanoemulsions here presented
represent a positively charged system with modified surface by
the presence of thermosensitive block copolymer with the ability to
increase bioadhesion of the droplets in the corneal epithelium
improving the riboflavin permeation to stroma.
Determination of Riboflavin Absorption Spectra
The absorption of ultraviolet, visible, and infrared radiation
depends on the structures of molecules and is typical for each
substance. Initially, we determined the absorption spectra of the
riboflavin nanoemulsions to verify the wavelength of maximum
absorption. Samples of 0.5% riboflavin were diluted with distilled
water to obtain values of maximum absorbance less than 1.00.
Sample absorbances were determined using a spectrophotom-
eter (Ultrospec 2000, Pharmacia Biotech, Piscataway, NJ, USA)
with quartz cuvettes and the standard 10 mm light path, in the
wavelength range from 300 to 600 nm. Distilled water was used as
a reference in spectrophotometer readings.
Table 1. Diameter of nanoemulsion after preparation.
Sample Diameter (nm) Mean (n=10) Polidispersity Index Zeta Potential (mV)
Unloaded nanoemulsion 67.8 0.254 +43.1
Riboflavin-5-loaded nanoemulsion 78.3 0.274 +31.3
doi:10.1371/journal.pone.0066408.t001
Figure 1. Stability evaluation of the nanoemulsions over time. Key: (%) Unloaded nanoemulsion (R = 0.9965); (#) Riboflavin-5-loaded
nanoemulsion (R = 0.9927). Mean of 10 analytical determinations 6 standart deviation.
doi:10.1371/journal.pone.0066408.g001
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Experimental Procedures
One-hundred and sixty freshly enucleated eyes (within 6 h of
death) from New Zealand rabbits obtained from the local
slaughterhouse (Coelho Real – Salto de Pirapora – SP - Brazil)
were used for the study (permission was obtained from this
slaughterhouse to use these animal parts). The age of the rabbits at
the time of death was approximately 90 days. Each specimen
underwent slit lamp evaluation, using direct and indirect
illumination. Only clear corneas with no edema were used. The
specimen was discarded if there was corneal scarring, opacity, or
other abnormalities. The corneal thickness, before and after
epithelium removal, was measured in all eyes using ultrasound
pachymetry (DGH Pachette 3, Exton, PA, USA).
Twenty eyes were not treated with riboflavin solution, but were
used to calculate the UVA absorption coefficient at 365 nm of the
cornea and to investigate the influence of epithelial removal. Ten
of the eyes had the epithelium from the central 8 mm cornea
removed using a blunt spatula before measurement.
The remaining 140 eyes were divided into the following groups:
I. Standard (n= 10). Eyes with de-epithelialized corneas
were soaked with standard hydrophilic riboflavin for
30 minutes. This group was used to evaluate riboflavin
absorption characteristics during the standard CXL
treatment.
II. Standard with intact epithelium (n = 25). Eyes with intact
corneal epithelium were soaked with standard hydrophilic
riboflavin (0.1% riboflavin-dextran solution) for 30, 60,
120, 180, or 240 minutes (n = 5 at each time point). This
group was used to evaluate the possibility of increasing
riboflavin absorption by prolonging the exposure time.
III. Concentrated with intact epithelium (n= 25). Eyes with
intact corneal epithelium were soaked with concentrated
hydrophilic riboflavin (1% riboflavin-dextran solution) for
30, 60, 120, 180, or 240 minutes (n = 5 at each time
point). This group was used to evaluate whether the
increase in concentration of standard riboflavin formula-
tion would increase the uptake through the intact
epithelium.
IV. Riboflavin-5-phosphate nanoemulsion (n= 25). Eyes with
intact corneal epithelium were soaked with 0.5% ribofla-
vin-5-phosphate nanoemulsion for 30, 60, 120, 180, or
240 minutes (n = 5 at each time point).
V. Riboflavin-base nanoemulsion (n= 25). Eyes with intact
corneal epithelium were soaked with 0.5% riboflavin-base
nanoemulsion for 30, 60, 120, 180, or 240 minutes (n = 5
at each time point).
VI. De-epithelialized riboflavin-5-phosphate nanoemulsion
(n= 15). Eyes with de-epithelialized corneas were soaked
with 0.5% riboflavin-5-phosphate nanoemulsion for
30 minutes. This group was used to evaluate stromal
affinity of the riboflavin-5-phosphate amphiphilic formu-
lation.
VII. De-epithelialized riboflavin-base nanoemulsion (n = 15).
Eyes with de-epithelialized corneas were soaked with 0.5%
riboflavin-base nanoemulsion for 30 minutes. This group
was used to evaluate stromal hydrophilic affinity of the
riboflavin-base formulation.
Corneas were soaked with the riboflavin solutions to compen-
sate for the drops running off the globe because of the absence of
eyelids. After exposure to the solutions at room temperature,
corneas were gently rinsed with balanced salt solution to remove
the excess of riboflavin. An 8 mm corneal button was trephined
after epithelial integrity had been assured by slit lamp examina-
tion. In groups IV and V, the epithelium was removed and
absorption measurements were repeated to evaluate riboflavin
retention in the epithelium.
Absorption and Transmittance Evaluation
Corneal transmittance was measured by placing the excised
corneas between the UVA light source (X-LinkH; Opto Eletronica,
Sao Carlos, Brazil) and an external photometer (MRUR-202,
Instrutherm, Sao Paulo, Brazil). This photometer was set at
365 nm, with a specific spectrum ranging from 320 to 390 nm.
Measurements were taken in controlled ambient light to avoid any
external interference.
An 8-mm UVA (365 nm) spot was applied 45 mm from the
cornea, with a surface irradiance of 3 mW/cm2. Surface
irradiance was continuously controlled by a microprocessor in
the monitoring system of the device that used an internal power
meter.
The absorption coefficient (m) and transmittance (T) were
calculated by the Lambert-Beer formula using the measured
corneal thickness (x), incident light intensity (I0) and transmitted
light intensity (I):
m~
{ln(I=I0)
x
T~
I
I0
The Lambert-Beer Law expresses the relationship between the
amount of absorbed light and the concentration of the solution
(i.e., the lower the light transmitted by a solution, the higher its
concentration).
Statistical Analysis
Pairwise comparison between groups was performed using the
Mann-Whitney test. All statistical analyses were performed with
commercially available software (Stata version 10; StataCorp,
College Station, TX). The alpha level (type I error) was set at 0.05.
Results are presented as the average 6 standard deviation.
Results
The average central corneal thickness measured with ultrasound
was 580.0652.8 mm and 529.0649.3 mm, before and after
epithelium removal, respectively. Both formulations of riboflavin
tested showed absorption peaks between 360 and 375 nm
(Figure 2). Thus, we used a solid-state device, available in our
laboratory, set at 365 nm.
Absorption and transmittance results are summarized in Table 2
and examples of corneas from the different groups are shown in
Figure 3. Removing the epithelium had no significant effect on the
absorption characteristics of rabbit corneas that were not exposed
to riboflavin. Absorption coefficients were 18.3460.65 cm21 and
18.5360.22 cm21, with and without epithelium, respectively
(P=0.068).
After exposure to 0.1% riboflavin solution to de-epithelialized
corneas for 30 minutes (Group I - Standard), transmittance and
absorption coefficients were 17.0060.51% and 32.8260.54 cm21,
respectively. These values were greatly different from the results
observed when the epithelium was left intact (Group II - Standard
Nanostructured Riboflavin for Epi-on Crosslinking
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with Intact Epithelium) using the same exposure time
(34.2060.37%, p=0.002 and 18.5060.19 cm21, p=0.002) and
even after 240 minutes of exposure (32.9460.25%, p=0.002 and
19.1560.15 cm21, p=0.002).
Increasing the concentration of the standard hydrophilic
solution to 1% (Group III) did not cause similar riboflavin
penetration through the intact epithelium, when compared to
Group II (p=0.008). After 240 minutes of exposure to the 1%
concentrated riboflavin solution, absorption coefficient
(20.3460.16 cm21) and transmittance (30.7460.29%) were sig-
nificantly different from the Standard Group (P=0.0021).
Figure 4 shows the transmittance and absorption coefficients of
corneas exposed to the riboflavin nanoemulsions (Groups IV and
V). In Group IV (0.5% riboflavin-5-phosphate), transmittance was
not different to the standard technique after 120 minutes (p=0.08)
and became greater at 240 minutes (p=0.002). Macroscopically, a
homogenous yellow stain representing riboflavin diffusion into the
stroma was observed (Figure 5). The absorption coefficient was not
statistically different from the standard group after 240 minutes
(P=0.54).
The absorption coefficient (p=0.0076) and transmittance
(p=0.0076) of the riboflavin-base nanoemulsion (Group V) were
higher than the standard formulation in an intact epithelium
(Group II). However, after 240 minutes, the values were still
significantly different than the standard protocol (Group I;
p=0.002 for absorption coefficient and transmittance).
Measurements taken on the same corneas of Group IV and V
after epithelium removal showed that both nanoemulsions were
able to diffuse into the corneal stroma. Corneal absorption
measurements were greater in these corneas compared to the
standard group with epithelium (Group II). Mean absorption
coefficient and transmittance were 18.5460.39% (p=0.0086) and
31.3560.44 cm21 (p=0.0086), for the riboflavin-5-phosphate
nanoemulsion and 25.2060.67% (p=0.0086) and
25.5360.48 cm21 (p=0.0086), for the riboflavin-base nanoemul-
sion. Riboflavin-5-phosphate nanoemulsion diffused into the
stroma better than the riboflavin-base nanoemulsion (p=0.008
for absorption coefficient and transmittance).
When eyes with debrided corneas were exposed to the
nanoemulsions (Groups VI and VII), riboflavin-5-phosphate had
a greater stromal affinity than its base counterpart. After
30 minutes, the transmittance was 4.2660.29% and the absorp-
tion coefficient was 58.4461.20 cm21. These values were
statistically different than the riboflavin-base values of
20.461.28% (P=0.008) and 29.4761.17 cm21 (P=0.008), re-
spectively.
Discussion
During CXL, stromal diffusion of riboflavin is necessary
because it is the basis of CXL safety and effectiveness. Riboflavin
is not only important as a photosensitizer, but also because it
shields UVA light from damaging the underlying ocular structures
such as the endothelium, lens, and retina. UVA radiation
decreases as it passes through the cornea, because riboflavin in
the cornea absorbs the highest amount of UVA, preventing high
doses of this radiation from reaching the posterior ocular
structures [36,37]. Until now, epithelium removal is the standard
method to facilitate penetration of riboflavin into the corneal
stroma. In the present study, we describe a new option to achieve
stromal diffusion of riboflavin without removal of the epithelium
and without the use of benzalkoniun chloride.
Our group has reported that the epithelium prevents the
penetration of the standard 0.1% riboflavin-dextran solution, but
apparently does not block UVA radiation [4]. Although the
epithelium can potentially block some UV radiation, its absorption
is greatest for wavelengths lower than 300 nm [38]. Therefore,
efficacy of CXL should not be decreased in the transepithelial
technique with the nanostructured riboflavin presented in this
study because both UVA radiation and riboflavin can penetrate
the corneal stroma.
After applying riboflavin in dextran solution to the de-
epithelialized rabbit corneas for 30 minutes (standard CXL
protocol), the absorption coefficient was 32.8260.54 cm21 and
the resulting transmittance was 17.0060.51%. Previous reports
presented higher levels (63 cm21 for rabbit corneas [36],
51.46 cm21 for porcine corneas [11], and 56.36 cm21 for human
corneas [11]). This may be explained because the riboflavin film
was included in these measurments. With removal of the riboflavin
film from the stromal surface, our values are consistent with
Figure 2. Absorption spectra of riboflavin-5-phosphate nanoemulsion and riboflavin-base nanoemulsion.
doi:10.1371/journal.pone.0066408.g002
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previous reports [11,22]. Using 0.5% riboflavin-5-phosphate
nanoemulsion for 4 hours in corneas with intact epithelium, we
observed comparable absorption values to the standard de-
epithelialized CXL treatment. This indicates that, although the
exposure time was long, this new riboflavin nanoemulsion was able
to penetrate efficiently the epithelium of rabbit corneas.
Permeability is dependent on the chemical affinity and the size
of the diffusing molecule. Our experiments show that riboflavin
penetration across an intact epithelium was possible, however,
240 min of exposure was required, probably due to the high
molecular weight of riboflavin (376.32 g/mol). Recently, the
results of another study on the same topic illustrated the utility of
using a synthetic peptide (NC-1059) to allow riboflavin to pass
through the intact epithelium, reaching concentrations almost as
high as if epithelium had been scraped off first [27]. Study data
demonstrated that NC-1059 transiently opened the epithelial
intercellular tight junctions by forming a nonselective ion channel
that reversibly alters epithelial barrier function without killing
corneal epithelial cells. In the future, combination of the synthetic
peptide described by Zhang et al with the present riboflavin-5-
phosphate nanoemulsion might allow a faster diffusion of
riboflavin through the intact epithelium [27].
Although topical instillation of drugs is very popular in
ophthalmology, the cornea is an effective barrier to hydrophilic
drugs such as the standard riboflavin solution. Corneal epithelium
is lipophilic and has annular tight junctions that completely
surround and effectively seal the superficial epithelial cells. Many
methods have been developed to enhance transepithelial absorp-
tion of hydrophilic therapeutic agents. One approach is to modify
the physicochemical property of drugs by nanotechnology.
Colloidal delivery systems based on microemulsions or nanoe-
mulsions are increasingly being utilized in the food and
pharmaceutical industries to encapsulate, protect, and deliver
bioactive components [28]. The small size of the particles in these
kinds of delivery systems (r,100 nm) means that they have a
number of potential benefits for certain applications, such as
enhanced long-term stability; high optical clarity and increased
bioavailability. Nanoemulsions are potent drug delivery vehicles
for ophthalmic use due to their sustained effect and high ability of
drug penetration into the deeper layers of the ocular structure and
the aqueous humor [39]. To date, a range of drugs has been
formulated in a nanoemulsion for ophthalmic application,
including dorzolamide hydrochloride [40] and indomethacin [41].
The role of penetration enhancers played by the amphiphilic
components of the nanoemulsion and the internal mobility of the
drug within the vehicle also contribute to its overall performance
in drug delivery. Amphiphile describes chemical compounds
containing both hydrophilic and lipophilic properties. Amphiphilic
molecules have a polar, water-soluble group attached to a non-
polar, water-insoluble hydrocarbon chain. An amphiphilic drug
has greater penetration through both the lipophilic epithelium and
the corneal stroma, which has hydrophilic characteristics. Based
on this concept, we developed two amphiphilic formulations
(nanoemulsions) using different riboflavins (phosphate and base).
Riboflavin-5-phosphate is a hydrophilic salt that can be delivered
to the stroma using the amphiphlic vehicle, despite the lipophilic
characteristics of the epithelium. Because the riboflavin-5-phos-
phate has hydrophilic properties, it is retained at a greater
concentration in the stroma. However, although the riboflavin-
base is able to pass through the epithelium, it cannot be retained in
the stroma, due to the lipophilic characteristics of the salt. Our
study showed that the riboflavin-5-phosphate nanoemulsion had a
better diffusion into the stroma of corneas with intact epithelium
than the riboflavin-base.
Transepithelial CXL has been suggested as an alternative
approach to overcome the inherent disadvantages of epithelial
scrapping. However, none of the previous proposed methods has
proven to saturate the stroma comparably to the standard CXL
protocol. As the absorption values of the new riboflavin-5-
phosphate nanoemulsion at 240 minutes were similar to those
obtained by corneas with removal of the epithelium in the
standard CXL protocol, transepithelial approach using this
formulation might be an alternative approach to overcome
limitations of previously proposed methods.
Figure 3. Photograph of the corneal buttons of rabbit eyes of
after exposure to different riboflavins. Corneas with intact
epithelium (A, B, and C) after exposure to 0.1% riboflavin-dextran
solution for 30 minutes (A) and for 240 minutes (B), as well as after
exposure to concentrated 1% riboflavin-dextran for 240 minutes (C).
De-epithelialized cornea soaked with 0.1% riboflavin-dextran for
30 minutes - standard technique (D). The yellow staining shows that
riboflavin diffused into the stroma only when the epithelium was
removed.
doi:10.1371/journal.pone.0066408.g003
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One of the limitations of this study is the use of dissected
rabbit eyes. It is not possible to obtain a homogeneous sample
size using human donor corneas. We decided to use rabbit
corneas because of their similarities with human corneas.
Porcine eyes were not chosen because of the thick stroma and
epithelium, which could result in a low value for the absorption
coefficient. Previous studies have demonstrated that bovine
freshly enucleated eyes can be used to evaluate corneal
permeability [26]. Although there is no scientific evidence of
which is best animal model for the study of corneal permeability,
the thickness seems to play an important role. When considering
the treatment of thin human corneas, as in keratoconus, the
rabbit model may be suitable [42]. To limit corneal edema and
the resulting increase in corneal thickness, only fresh eyes less
than 6 h after euthanization were used for measurements.
However, further research on the safety and efficacy must be
done before using this drug in patients. Although, riboflavin
absorption into to the stroma is an essential step for CXL
treatment and its evaluation is essential before conducting
clinical studies; further experiments are needed to evaluate the
mechanical characterization of cross-linked corneas using the
new riboflavin nanoemulsion. Further studies should evaluate
Figure 4. Change of transmittance and absorption coefficient of rabbit corneas in the course of time. Transmittance change (A) and
absorption coefficient change (B) of corneas soaked with riboflavin formulations. Dashed lines show group I values (standard treatment).
doi:10.1371/journal.pone.0066408.g004
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safety and effectiveness of the use riboflavin drops for a few hours
before being treated with 30 minutes of UVA irradiation.
In this study we demonstrated that riboflavin nanoemulsion
could be delivered into the stroma in corneas with intact
epithelium. We were able to obtain stromal concentrations of
riboflavin similar to the standard CXL technique in de-epitheli-
alized corneas. The riboflavin-5-phosphate nanoemulsion more
efficiently diffused into the stroma than the riboflavin-base
nanoemulsion. To the best of our knowledge, this is the first
study using a riboflavin nanoemulsion to achieve epithelial
permeation of the drug. The present study may have significant
implications for the refinement of the CXL technique. With the
development of riboflavin nanoemulsion, the transepithelial
technique may in a near future become a real option in CXL
treatment.
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